Proteomics

Dataset Information

0

Beta-blocker/ACE inhibitor therapy differentially impacts the steady state signaling landscape of failing and non-failing hearts.

ABSTRACT: Rationale: The molecular underpinnings of heart failure with reduced ejection fraction (HFrEF) involves a complex remodeling of the contractile, metabolic and electrical functions. Current pharmacotherapy for patients presenting HFrEF includes combination of angiotensin-converting enzyme inhibitors (ACEi) and β-adrenergic receptor blockers (β-AR blockers). Yet, a knowledge gap exists regarding the molecular changes accompanying such treatment. Objective: The present study takes an omics approach to study protein and phosphorylation signaling derangement in HFrEF and to define the global changes resulting from treatment with β-AR blocker (metoprolol) and ACE inhibitor (enalapril) in control- and HFrEF hearts.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Heart

SUBMITTER: Navratan Bagwan  

LAB HEAD: Alicia Lundby

PROVIDER: PXD024525 | Pride | 2022-05-20

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
20151130_QE7_UPLC11_NL_Heart_Failure_Mouse_Heart_01_Left_Ventricle_Fraction_01.raw Raw
20151130_QE7_UPLC11_NL_Heart_Failure_Mouse_Heart_01_Left_Ventricle_Fraction_02.raw Raw
20151130_QE7_UPLC11_NL_Heart_Failure_Mouse_Heart_01_Left_Ventricle_Fraction_03.raw Raw
20151130_QE7_UPLC11_NL_Heart_Failure_Mouse_Heart_01_Left_Ventricle_Fraction_04.raw Raw
20151130_QE7_UPLC11_NL_Heart_Failure_Mouse_Heart_01_Left_Ventricle_Fraction_05.raw Raw
Items per page:
1 - 5 of 244
altmetric image

Publications

Beta-blocker/ACE inhibitor therapy differentially impacts the steady state signaling landscape of failing and non-failing hearts.

Sorrentino Andrea A   Bagwan Navratan N   Linscheid Nora N   Poulsen Pi C PC   Kahnert Konstantin K   Thomsen Morten B MB   Delmar Mario M   Lundby Alicia A  

Scientific reports 20220319 1

Heart failure is a multifactorial disease that affects an estimated 38 million people worldwide. Current pharmacotherapy of heart failure with reduced ejection fraction (HFrEF) includes combination therapy with angiotensin-converting enzyme inhibitors (ACEi) and β-adrenergic receptor blockers (β-AR blockers), a therapy also used as treatment for non-cardiac conditions. Our knowledge of the molecular changes accompanying treatment with ACEi and β-AR blockers is limited. Here, we applied proteomic  ...[more]

Similar Datasets

Proteomics The protein expression landscape of the heart across humans and model organisms
2021-02-03 | PXD012636 | Pride
Proteomics A common gene signature of the right ventricle in failing rat and human hearts
2024-04-11 | PXD047022 | Pride
Proteomics Neuronal cells from ASL patients
2021-05-11 | PXD020316 | Pride
Transcriptomics Expression data from murine cardiac tissue
2011-12-31 | E-GEOD-22881 | biostudies-arrayexpress
Transcriptomics Microarray analysis of TAP::ALG-1 associated RNAs isolated from synchronized 'wild-type' animals and 'mir-58' mutants
2012-03-01 | E-GEOD-32942 | biostudies-arrayexpress
Transcriptomics CpG islands Methylation Profiling by DMH in Epithelial Ovarian Cancer: Screening Set
2011-06-01 | E-GEOD-23240 | biostudies-arrayexpress
Transcriptomics Homarus americanus larval development and metamorphosis
2013-12-31 | E-GEOD-45683 | biostudies-arrayexpress
Transcriptomics Primary human CD34+ cells for modeling ETO2-GLIS2 leukemogenesis - ATACseq
2024-10-08 | E-MTAB-14124 | biostudies-arrayexpress
Proteomics System-wide identification of enzyme substrates by thermal analysis (SIESTA)
2021-01-11 | PXD014445 | Pride
Proteomics Helical superstructures between amyloid and collagen VI in heart derived fibrils from a patient with Light Chain Amyloidosis
2024-07-02 | PXD049301 | Pride